scholarly article | Q13442814 |
P2093 | author name string | Lingyun Li | |
Amyn M Rojiani | |||
Dietmar W Siemann | |||
P433 | issue | 1 | |
P304 | page(s) | 91-97 | |
P577 | publication date | 2002-01-01 | |
P1433 | published in | Acta Oncologica | Q326164 |
P1476 | title | Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma | |
P478 | volume | 41 |
Q28543671 | A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models |
Q83390306 | A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) |
Q35909593 | Antineoplastic agents. 515. Synthesis of human cancer cell growth inhibitors derived from 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene |
Q78594497 | Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126 |
Q44412196 | Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo |
Q37458557 | Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). |
Q33183693 | Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. |
Q40328661 | Evaluations of the renal cell carcinoma model Caki-1 using a silicon based microvascular casting technique |
Q42203737 | Radiotherapy in combination with vascular-targeted therapies |
Q26781365 | Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? |
Q34122191 | The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents |
Q37254370 | Vascular targeted therapies in oncology |
Q35805639 | Vascular-targeting therapies for treatment of malignant disease. |
Search more.